{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:58:14Z","timestamp":1786982294015,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s12185-011-0967-8","type":"journal-article","created":{"date-parts":[[2011,12,2]],"date-time":"2011-12-02T08:08:55Z","timestamp":1322813335000},"page":"580-582","source":"Crossref","is-referenced-by-count":3,"title":["Successful treatment with gemtuzumab ozogamicin and donor lymphocyte infusion for acute myeloid leukemia relapsing after allogeneic stem cell transplantation"],"prefix":"10.1007","volume":"94","author":[{"given":"Takayoshi","family":"Tachibana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Takasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Numata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuo","family":"Maruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiraku","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ishigatsubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiwa","family":"Kanamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,2]]},"reference":[{"issue":"1","key":"967_CR1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.1840040121","volume":"4","author":"GB McDonald","year":"1984","unstructured":"McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4(1):116\u201322.","journal-title":"Hepatology"},{"issue":"10","key":"967_CR2","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.bbmt.2007.06.007","volume":"13","author":"M Mielcarek","year":"2007","unstructured":"Mielcarek M, Storer BE, Flowers ME, Storb R, Sandmaier BM, Martin PJ. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2007;13(10):1160\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"967_CR3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/bmt.2009.300","volume":"44","author":"BN Savani","year":"2009","unstructured":"Savani BN, Mielke S, Reddy N, Goodman S, Jagasia M, Rezvani K. Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplant. 2009;44(12):769\u201377.","journal-title":"Bone Marrow Transplant"},{"key":"967_CR4","doi-asserted-by":"crossref","unstructured":"Thakar MS, Forman SJ. ASH evidence-based guidelines: is there a role for second allogeneic transplant after relapse? Hematology Am Soc Hematol Educ Program. 2009:414\u20138 (review).","DOI":"10.1182\/asheducation-2009.1.414"},{"key":"967_CR5","doi-asserted-by":"crossref","unstructured":"Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2011. doi: 10.1038\/leu.2011.234 (epub ahead of print).","DOI":"10.1038\/leu.2011.234"},{"issue":"7","key":"967_CR6","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","volume":"104","author":"RA Larson","year":"2005","unstructured":"Larson RA, Sievers EL, Stadtmauer EA, L\u00f6wenberg B, Estey EH, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104(7):1442\u201352.","journal-title":"Cancer"},{"issue":"5","key":"967_CR7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s12185-009-0440-0","volume":"90","author":"M Sumi","year":"2009","unstructured":"Sumi M, Ichikawa N, Nasu K, Shimizu I, Ueki T, Ueno M, et al. Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation. Int J Hematol. 2009;90(5):643\u20137.","journal-title":"Int J Hematol"},{"issue":"6","key":"967_CR8","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/sj.leu.2405029","volume":"22","author":"H Tamai","year":"2008","unstructured":"Tamai H, Shioi Y, Yamaguchi H, Okabe M, Wakita S, Mizuki T, et al. Treatment of relapsed acute myeloid leukemia with MLL\/AF6 fusion after allogeneic hematopoietic stem cell transplantation with gemtuzumab ozogamicin with a long interval followed by donor lymphocyte infusion. Leukemia. 2008;22(6):1273\u20134.","journal-title":"Leukemia"},{"issue":"2","key":"967_CR9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1620\/tjem.220.121","volume":"220","author":"T Ando","year":"2010","unstructured":"Ando T, Mitani N, Matsunaga K, Nakazora T, Gondo T, Yujiri T, et al. Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation. Tohoku J Exp Med. 2010;220(2):121\u20136.","journal-title":"Tohoku J Exp Med"},{"issue":"8","key":"967_CR10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ncponc0899","volume":"4","author":"T Owonikoko","year":"2007","unstructured":"Owonikoko T, Agha M, Balassanian R, Smith R, Raptis A. Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant. Nat Clin Pract Oncol. 2007;4(8):491\u20135.","journal-title":"Nat Clin Pract Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-011-0967-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-011-0967-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-011-0967-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T01:34:04Z","timestamp":1560994444000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-011-0967-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["967"],"URL":"https:\/\/doi.org\/10.1007\/s12185-011-0967-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}